Melanoma Clinical Trials in Maryland

Showing 161-180 of 354 trials

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

NCT00019396

RATIONALE: The drug flt3L may stimulate a person's immune system and help to kill tumor cells. Vaccines made from melanoma cells may make the body build an immune response to and kill their tumor cells. PURPOSE: Phase II trial to study the effectiveness of flt3L with or without vaccine therapy in treating patients with metastatic melanoma or renal cell cancer.

Stage IV MelanomaStage IV Renal Cell CancerRecurrent Renal Cell Cancer+1 more

National Cancer Institute (NCI)Started Feb 1998

Bethesda, Maryland, United States

COMPLETEDPhase 217 miles

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

NCT03679767

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.

Metastatic Non-small Cell Lung CancerLocally Advanced Urothelial CancerMetastatic Urothelial Cancer+4 more

Incyte Corporation121 participantsStarted Jan 2019

Fresno, California, United States • Fresno, California, United States • San Marcos, California, United States +49 more locations

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Melanoma Trials in Other Cities

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Behavioral Weight Loss Program for Cancer Survivors in Maryland

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma

Study in Subjects With Small Primary Choroidal Melanoma

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Study of ASN003 in Subjects With Advanced Solid Tumors

Other Conditions in Maryland